Sign in

CIK 0001672619

  • Non-accelerated filer

Enliven Therapeutics, Inc.

Sign in to watch
Ticker
ELVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
811523849
Phone
+1 650-547-5814
Business address
205 PARK ROAD, BURLINGAME, CA, 94010
Former names
IMARA Inc.
  1. 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 20,000 shares at an average $26.75 ($535,099)
  2. 4 Planned sale Director sold 1,230 shares at an average $26.75 ($32,902)
  3. 4 Planned sale CHIEF OPERATING OFFICER sold 48,300 shares at an average $27.99 ($1,351,762)
  4. 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 132,500 shares at an average $26.23 ($3,476,014)
  5. 4 Planned sale Director sold 13,920 shares at an average $25.02 ($348,281)
  6. 4 Derivatives Options or other derivatives
  7. 3 Insider Initial Statement of Ownership
  8. 4 Exercise or conversion CHIEF FINANCIAL OFFICER acquired 13,000 shares (option exercise)
  9. 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 5,000 shares at $16.84 ($84,206)
  10. 4 Exercise or conversion Director acquired 15,958 shares (option exercise)
  11. 4 Derivatives Options or other derivatives
  12. 3 Insider Initial Statement of Ownership
  13. 4 Planned sale CHIEF OPERATING OFFICER sold 6,663 shares at an average $21.02 ($140,073)
  14. 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,500 shares at an average $22.33 ($279,155)
  15. 4 Planned sale PRESIDENT AND CEO sold 12,500 shares at $21.82 ($272,739)
  16. 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at an average $17.40 ($116,034)
  17. 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,500 shares at $22.08 ($276,025)
  18. 4 Planned sale PRESIDENT AND CEO sold 12,500 shares at $21.33 ($266,654)
  19. 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at $20.10 ($133,993)
  20. 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at $20.40 ($66,291)

Page 3 of 20 · 383 filings